8-K 1 westpharm-8k_53888.txt WEST PHARMACEUTICAL 8-K FILING -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 -------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) of the SECURITIES EXCHANGE ACT OF 1934 Date of earliest event reported: August 29, 2002 -------------- WEST PHARMACEUTICAL SERVICES, INC. -------------- (Exact name of registrant as specified in charter) Pennsylvania 1-8036 23-1210010 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) -------------- 101 Gordon Drive, P.O. Box 645, Lionville, Pennsylvania 19341-0645 -------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (610) 594-2900 -------------- (Registrant's telephone number, including area code) ---------N/A-------- (Former name or former address, if changed since last report) ------------------------------------------------------------------------------- Item 7. Financial Statements, Pro Forma Financial Information and Exhibits (c) Exhibits Exhibit No. Description ---------- ------------ 99.1 Certification by Donald E. Morel, Jr., President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 99.2 Certification by Linda R. Altemus, Vice President and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Item 9. Regulation FD Disclosure On August 29, 2002, Donald E. Morel, Jr., President and Chief Executive Officer, and Linda R. Altemus, Vice President and Chief Financial Officer, of West Pharmaceutical Services, Inc. each delivered to the Securities and Exchange Commission ("SEC") a certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Copies of the certifications of Donald E. Morel, Jr. and Linda R. Altemus are filed herewith as Exhibits 99.1 and 99.2, respectively. Limitation of Incorporation by Reference In accordance with general instruction B.2 of Form 8-K, the information in this report is furnished pursuant to Item 9 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. WEST PHARMACEUTICAL SERVICES, INC. Date: August 29, 2002 By: /s/ Linda R. Altemus ------------------------------------ Linda R. Altemus Vice President and Chief Financial Officer Exhibit Index Exhibit No. Description ---------- ----------- 99.1 Certification by Donald E. Morel, Jr., President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 99.2 Certification by Linda R. Altemus, Vice President and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002